BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 16162081)

  • 1. Pramipexole in the treatment of Parkinson's disease: new developments.
    Möller JC; Oertel WH
    Expert Rev Neurother; 2005 Sep; 5(5):581-6. PubMed ID: 16162081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
    Künig G; Pogarell O; Möller JC; Delf M; Oertel WH
    Clin Neuropharmacol; 1999; 22(5):301-5. PubMed ID: 10516884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
    Noyes K; Dick AW; Holloway RG;
    Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
    Piercey MF
    Clin Neuropharmacol; 1998; 21(3):141-51. PubMed ID: 9617505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
    J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
    Möller JC; Oertel WH; Köster J; Pezzoli G; Provinciali L
    Mov Disord; 2005 May; 20(5):602-10. PubMed ID: 15726540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramipexole and ropinirole for Parkinson's disease.
    Med Lett Drugs Ther; 1997 Nov; 39(1014):109-10. PubMed ID: 9398824
    [No Abstract]   [Full Text] [Related]  

  • 10. Dopamine agonists in Parkinson's disease.
    Yamamoto M; Schapira AH
    Expert Rev Neurother; 2008 Apr; 8(4):671-7. PubMed ID: 18416667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A; Althoff R; Martineau RJ; Jacobson J
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pramipexole in Parkinson disease. Results of a treatment observation].
    Reichmann H; Brecht HM; Kraus PH; Lemke MR
    Nervenarzt; 2002 Aug; 73(8):745-50. PubMed ID: 12242961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease.
    Lemke MR; Brecht HM; Koester J; Reichmann H
    J Neurol Sci; 2006 Oct; 248(1-2):266-70. PubMed ID: 16814808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of sudden onset of sleep in Parkinson's disease.
    Körner Y; Meindorfner C; Möller JC; Stiasny-Kolster K; Haja D; Cassel W; Oertel WH; Krüger HP
    Mov Disord; 2004 Nov; 19(11):1298-305. PubMed ID: 15389999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of pramipexole on depressive symptoms in Parkinson's disease.
    Yasui N; Sekiguchi K; Hamaguchi H; Kanda F
    Kobe J Med Sci; 2011 Feb; 56(5):E214-9. PubMed ID: 21937869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of pramipexole in Parkinson's disease in the US.
    Hoerger TJ; Bala MV; Rowland C; Greer M; Chrischilles EA; Holloway RG
    Pharmacoeconomics; 1998 Nov; 14(5):541-57. PubMed ID: 10344917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dopamine agonist is effective in Parkinson disease not only against tremor. Depression is also improved].
    MMW Fortschr Med; 2002 May; Suppl 2():88. PubMed ID: 12070869
    [No Abstract]   [Full Text] [Related]  

  • 20. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study.
    Pogarell O; Gasser T; van Hilten JJ; Spieker S; Pollentier S; Meier D; Oertel WH
    J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):713-20. PubMed ID: 12023411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.